WO2008120472A1 - 高脂血症の予防及び/又は治療剤 - Google Patents
高脂血症の予防及び/又は治療剤 Download PDFInfo
- Publication number
- WO2008120472A1 WO2008120472A1 PCT/JP2008/000788 JP2008000788W WO2008120472A1 WO 2008120472 A1 WO2008120472 A1 WO 2008120472A1 JP 2008000788 W JP2008000788 W JP 2008000788W WO 2008120472 A1 WO2008120472 A1 WO 2008120472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- prophylactic
- hyperlipemia
- disclosed
- blood
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2680407A CA2680407C (en) | 2007-03-29 | 2008-03-28 | Prophylactic and/or therapeutic agent for hyperlipidemia |
AT08720655T ATE549323T1 (de) | 2007-03-29 | 2008-03-28 | Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie |
EP08720655A EP2141155B1 (en) | 2007-03-29 | 2008-03-28 | Prophylactic and/or therapeutic agent for hyperlipidemia |
JP2009507415A JP5275975B2 (ja) | 2007-03-29 | 2008-03-28 | 高脂血症の予防及び/又は治療剤 |
KR1020097018191A KR101420319B1 (ko) | 2007-03-29 | 2008-03-28 | 고지혈증 예방 및/또는 치료제 |
ES08720655T ES2380752T3 (es) | 2007-03-29 | 2008-03-28 | Agente profiláctico y/o terapéutico para hiperlipidemia |
US12/593,356 US8426455B2 (en) | 2007-03-29 | 2008-03-28 | Prophylactic and/or therapeutic agent for hyperlipidemia |
CN2008800033811A CN101627021B (zh) | 2007-03-29 | 2008-03-28 | 高脂血症的预防和/或治疗剂 |
HK10104519.2A HK1138277A1 (en) | 2007-03-29 | 2010-05-10 | Prophylactic and/or therapeutic agent for hyperlipemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-087081 | 2007-03-29 | ||
JP2007087081 | 2007-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008120472A1 true WO2008120472A1 (ja) | 2008-10-09 |
Family
ID=39808058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/000788 WO2008120472A1 (ja) | 2007-03-29 | 2008-03-28 | 高脂血症の予防及び/又は治療剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8426455B2 (ja) |
EP (2) | EP2141155B1 (ja) |
JP (1) | JP5275975B2 (ja) |
KR (1) | KR101420319B1 (ja) |
CN (1) | CN101627021B (ja) |
AT (1) | ATE549323T1 (ja) |
CA (1) | CA2680407C (ja) |
ES (1) | ES2380752T3 (ja) |
HK (1) | HK1138277A1 (ja) |
PT (1) | PT2141155E (ja) |
TW (1) | TWI407955B (ja) |
WO (1) | WO2008120472A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011037223A1 (ja) * | 2009-09-28 | 2011-03-31 | 興和株式会社 | 内臓脂肪重量の低下剤 |
WO2014050134A1 (ja) * | 2012-09-27 | 2014-04-03 | 興和株式会社 | 脂質異常症治療剤 |
WO2015030033A1 (ja) * | 2013-08-28 | 2015-03-05 | 興和株式会社 | 脂質異常症治療剤 |
JP2019011325A (ja) * | 2017-06-30 | 2019-01-24 | 興和株式会社 | 医薬組成物 |
JP7356968B2 (ja) | 2018-05-08 | 2023-10-05 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102977085B (zh) * | 2011-10-27 | 2015-07-29 | 四川大学 | 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途 |
ES2847168T5 (es) | 2016-07-29 | 2024-02-20 | Kowa Co | Métodos para prevenir acontecimientos cardiovasculares en poblaciones dislipidémicas de riesgo residual |
US20200113873A1 (en) * | 2017-06-30 | 2020-04-16 | Kowa Company, Ltd. | Medicament |
CN110809470A (zh) * | 2017-06-30 | 2020-02-18 | 兴和株式会社 | 医药品 |
US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
JP2021506907A (ja) * | 2017-12-21 | 2021-02-22 | 興和株式会社 | 高トリグリセライド血症の治療方法 |
TWI829841B (zh) * | 2018-12-27 | 2024-01-21 | 日商興和股份有限公司 | 醫藥品 |
KR102289381B1 (ko) | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
US6511985B1 (en) | 1998-12-18 | 2003-01-28 | Bayer Aktiengesellschaft | Combination of cerivastatin and fibrates |
WO2003013608A1 (en) | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR |
DE10200138A1 (de) | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
WO2005023777A1 (ja) | 2003-09-03 | 2005-03-17 | Kowa Co., Ltd. | Ppar活性化化合物及びこれを含有する医薬組成物 |
WO2006090756A1 (ja) | 2005-02-25 | 2006-08-31 | Kyorin Pharmaceutical Co., Ltd. | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
US6777414B1 (en) | 1999-04-09 | 2004-08-17 | Meiji Seika Kaisha, Ltd. | Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same |
JP4901218B2 (ja) | 2004-02-09 | 2012-03-21 | あすか製薬株式会社 | 併用医薬 |
PL1852426T3 (pl) * | 2005-02-23 | 2014-04-30 | Kowa Co | Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego |
TW200714280A (en) | 2005-06-01 | 2007-04-16 | Takeda Pharmaceuticals Co | Novel method of treating hyperlipidemia |
-
2008
- 2008-03-20 TW TW097109834A patent/TWI407955B/zh active
- 2008-03-28 WO PCT/JP2008/000788 patent/WO2008120472A1/ja active Application Filing
- 2008-03-28 JP JP2009507415A patent/JP5275975B2/ja active Active
- 2008-03-28 PT PT08720655T patent/PT2141155E/pt unknown
- 2008-03-28 CA CA2680407A patent/CA2680407C/en not_active Expired - Fee Related
- 2008-03-28 KR KR1020097018191A patent/KR101420319B1/ko active IP Right Grant
- 2008-03-28 EP EP08720655A patent/EP2141155B1/en active Active
- 2008-03-28 US US12/593,356 patent/US8426455B2/en active Active
- 2008-03-28 ES ES08720655T patent/ES2380752T3/es active Active
- 2008-03-28 AT AT08720655T patent/ATE549323T1/de active
- 2008-03-28 EP EP11195053A patent/EP2433932A1/en not_active Withdrawn
- 2008-03-28 CN CN2008800033811A patent/CN101627021B/zh active Active
-
2010
- 2010-05-10 HK HK10104519.2A patent/HK1138277A1/xx unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
US5856336A (en) | 1987-08-20 | 1999-01-05 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones |
US6511985B1 (en) | 1998-12-18 | 2003-01-28 | Bayer Aktiengesellschaft | Combination of cerivastatin and fibrates |
WO2003013608A1 (en) | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR |
DE10200138A1 (de) | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
WO2005023777A1 (ja) | 2003-09-03 | 2005-03-17 | Kowa Co., Ltd. | Ppar活性化化合物及びこれを含有する医薬組成物 |
WO2006090756A1 (ja) | 2005-02-25 | 2006-08-31 | Kyorin Pharmaceutical Co., Ltd. | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 |
Non-Patent Citations (14)
Title |
---|
ATHEROSCLEROSIS, vol. 124, 1996, pages 103 - 117 |
ATHEROSCLEROSIS, vol. 29, 1978, pages 269 - 275 |
ATHEROSCLEROSIS, vol. 74, 1988, pages 15 - 21 |
BIOCHIM. BIOPHYS. ACTA, vol. 1254, 1995, pages 7 - 12 |
DIABETES CARE, vol. 25, 2002, pages 1198 - 1202 |
INOUE I. ET AL.: "Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARgamma/RXRalpha and Decrease the Transactivation of NFkappaB", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 290, no. 1, 2002, pages 131 - 139, XP002996645 * |
J. CLIN. THERAP. MED., vol. 17, 2001, pages 857 - 883 |
J. LIPID. RES., vol. 39, 1998, pages 75 - 84 |
J. PHARMACOL. SCI., vol. 103, no. 1, 2007, pages 244P |
JOHNSON T.E. ET AL.: "Statins and PPARgamma agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 208, no. 3, 2005, pages 210 - 221, XP003006969 * |
TANAKA T. ET AL.: "Koshiketsusho Gappei 2-gata Tonyobyo Kanja ni Taisuru Fenofibrate no Chokiteki Yuyosei", PROGRESS IN MEDICINE, vol. 26, 2006, pages 1111 - 1116, XP008142108 * |
TERAMOTO T.: "Koshiketsusho Chiryo ni Okeru Fibrate-kei Yakuzai no Ichizuke - Daikibo Rinsho Shiken o Furikaette -", THERAPEUTIC RESEARCH, vol. 27, no. 10, 2006, pages 1979 - 1986, XP008116832 * |
USUI ET AL., LIPID RES., vol. 43, 2002, pages 805 - 814 |
YAMAZAKI H. ET AL.: "Shinki HMG-CoA Kangen Koso Sogaiyaku Pitavastatin (Livalo-jo) no Yakuri Oyobi Yakubutsu Dotaiteki Tokucho to Rinsho Koka", FOLIA PHARMACOLOGICA JAPONICA, vol. 123, 2004, pages 349 - 362, XP008116671 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5679458B2 (ja) * | 2009-09-28 | 2015-03-04 | 興和株式会社 | 内臓脂肪重量の低下剤 |
WO2011037223A1 (ja) * | 2009-09-28 | 2011-03-31 | 興和株式会社 | 内臓脂肪重量の低下剤 |
US10258609B2 (en) | 2012-09-27 | 2019-04-16 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
WO2014050134A1 (ja) * | 2012-09-27 | 2014-04-03 | 興和株式会社 | 脂質異常症治療剤 |
JPWO2014050134A1 (ja) * | 2012-09-27 | 2016-08-22 | 興和株式会社 | 脂質異常症治療剤 |
EA024873B1 (ru) * | 2012-09-27 | 2016-10-31 | Кова Компани, Лтд. | Терапевтическое средство при дислипидемии |
US9572798B2 (en) | 2012-09-27 | 2017-02-21 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
US11013722B2 (en) | 2012-09-27 | 2021-05-25 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
US9931321B2 (en) | 2012-09-27 | 2018-04-03 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
WO2015030033A1 (ja) * | 2013-08-28 | 2015-03-05 | 興和株式会社 | 脂質異常症治療剤 |
JP2018197273A (ja) * | 2013-08-28 | 2018-12-13 | 興和株式会社 | 脂質異常症治療剤 |
JPWO2015030033A1 (ja) * | 2013-08-28 | 2017-03-02 | 興和株式会社 | 脂質異常症治療剤 |
JP2019011325A (ja) * | 2017-06-30 | 2019-01-24 | 興和株式会社 | 医薬組成物 |
JP7356968B2 (ja) | 2018-05-08 | 2023-10-05 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
Also Published As
Publication number | Publication date |
---|---|
KR101420319B1 (ko) | 2014-07-16 |
KR20090129994A (ko) | 2009-12-17 |
PT2141155E (pt) | 2012-05-23 |
EP2141155B1 (en) | 2012-03-14 |
CA2680407C (en) | 2015-04-21 |
ES2380752T3 (es) | 2012-05-18 |
EP2141155A4 (en) | 2010-05-19 |
TWI407955B (zh) | 2013-09-11 |
US20100069433A1 (en) | 2010-03-18 |
US8426455B2 (en) | 2013-04-23 |
ATE549323T1 (de) | 2012-03-15 |
EP2141155A1 (en) | 2010-01-06 |
CN101627021B (zh) | 2012-11-28 |
HK1138277A1 (en) | 2010-08-20 |
EP2433932A1 (en) | 2012-03-28 |
TW200838510A (en) | 2008-10-01 |
JPWO2008120472A1 (ja) | 2010-07-15 |
CN101627021A (zh) | 2010-01-13 |
JP5275975B2 (ja) | 2013-08-28 |
CA2680407A1 (en) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008120472A1 (ja) | 高脂血症の予防及び/又は治療剤 | |
WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
WO2008102749A1 (ja) | 複素環化合物 | |
WO2009051244A1 (ja) | 複素環化合物 | |
WO2008093639A1 (ja) | ピラゾール化合物 | |
WO2007118185A3 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
WO2006112549A8 (ja) | 縮合複素環化合物 | |
WO2007095601A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
WO2008136428A1 (ja) | 含窒素5員複素環化合物 | |
WO2007003962A3 (en) | Gpcr agonists | |
WO2008011453A3 (en) | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | |
WO2007100535A3 (en) | Oxyntomodulin derivatives | |
WO2007125547A3 (en) | Novel process for statins and its pharmaceutically acceptable salts thereof | |
NO20035526D0 (no) | Forbindelser for behandling av metabolske forstyrrelser | |
MX2010009736A (es) | Compuesto heterociclico. | |
WO2008142859A1 (ja) | 新規なスピロオキシインドール化合物及びこれを含有する医薬 | |
GEP20105033B (en) | Therapeutic agent for diabetes | |
WO2007104789A3 (en) | Amylin derivatives | |
WO2007127726A3 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
WO2007127688A3 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
WO2010093849A3 (en) | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | |
WO2006074244A3 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
WO2006053043A3 (en) | Methods of treating diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880003381.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08720655 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097018191 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008720655 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2680407 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009507415 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12593356 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |